Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.
Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up. Steinberg MH, et al. Among authors: swerdlow p. Am J Hematol. 2010 Jun;85(6):403-8. doi: 10.1002/ajh.21699. Am J Hematol. 2010. PMID: 20513116 Free PMC article. Clinical Trial.
The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.
Smith WR, Ballas SK, McCarthy WF, Bauserman RL, Swerdlow PS, Steinberg MH, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Smith WR, et al. Among authors: swerdlow ps. Pain Med. 2011 May;12(5):697-705. doi: 10.1111/j.1526-4637.2011.01096.x. Epub 2011 Apr 11. Pain Med. 2011. PMID: 21481164 Free PMC article. Clinical Trial.
Hydroxyurea and sickle cell anemia: effect on quality of life.
Ballas SK, Barton FB, Waclawiw MA, Swerdlow P, Eckman JR, Pegelow CH, Koshy M, Barton BA, Bonds DR. Ballas SK, et al. Among authors: swerdlow p. Health Qual Life Outcomes. 2006 Aug 31;4:59. doi: 10.1186/1477-7525-4-59. Health Qual Life Outcomes. 2006. PMID: 16942629 Free PMC article. Clinical Trial.
Inpatient management of sickle cell pain: a 'snapshot' of current practice.
Miller ST, Kim HY, Weiner D, Wager CG, Gallagher D, Styles L, Dampier CD; Investigators of the Sickle Cell Disease Clinical Research Network (SCDCRN). Miller ST, et al. Am J Hematol. 2012 Mar;87(3):333-6. doi: 10.1002/ajh.22265. Epub 2012 Jan 9. Am J Hematol. 2012. PMID: 22231150 Free PMC article.
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.
Ataga KI, Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, Castro O, Vichinsky E, Kutlar A, Orringer EP, Rigdon GC, Stocker JW; ICA-17043-05 Investigators. Ataga KI, et al. Among authors: swerdlow p. Blood. 2008 Apr 15;111(8):3991-7. doi: 10.1182/blood-2007-08-110098. Epub 2008 Jan 11. Blood. 2008. PMID: 18192510 Free article. Clinical Trial.
Dose-escalation study of ICA-17043 in patients with sickle cell disease.
Ataga KI, Orringer EP, Styles L, Vichinsky EP, Swerdlow P, Davis GA, Desimone PA, Stocker JW. Ataga KI, et al. Among authors: swerdlow p. Pharmacotherapy. 2006 Nov;26(11):1557-64. doi: 10.1592/phco.26.11.1557. Pharmacotherapy. 2006. PMID: 17064199 Clinical Trial.
60 results